Myovant Sciences Ltd. (MYOV)
Chart Events
Performance Outlook
| Previous Close | 15.12 |
| Open | 16.41 |
| Bid | 16.80 x 800 |
| Ask | 16.92 x 800 |
| Day's Range | 16.08 - 17.49 |
| 52 Week Range | 7.67 - 27.43 |
| Volume | |
| Avg. Volume | 751,570 |
| Market Cap | 1.589B |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | Oct 24, 2022 - Oct 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MYOV
Related Research
- Myovant Sciences Ltd.Daily – Vickers Top Buyers & Sellers for 07/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat18 days agoArgus Research
- GlobeNewswire
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NE
- Simply Wall St.
What You Need To Know About Myovant Sciences Ltd.'s (NYSE:MYOV) Investor Composition
The big shareholder groups in Myovant Sciences Ltd. ( NYSE:MYOV ) have power over the company. Institutions will often...
- Motley Fool
Myovant Sciences Ltd. (MYOV) Q1 2022 Earnings Call Transcript
At this time, I would like to turn the call over to Uneek Mehra, chief financial and business officer at Myovant. Joining me for today's call, are Dave Marek, Myovant's chief executive officer; Lauren Merendino, chief commercial officer; and Dr. Juan Camilo Arjona, chief medical officer.
